



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 gp120 Monoclonal (5F7)
Catalog Number:	2533
Lot Number:	100271
Release Category:	D
Provided:	1 mL of culture supernatant
Description:	A monoclonal antibody to HIV-1 gp120, specifically the V3 loop (epitope: RIQRGPGRAFVTIGK)
Host:	Mouse
Titer:	The user should determine the optimal concentration for any application.
Special Characteristics:	<p>This antibody was produced in cell culture. It originates from a hybridoma. The hybridoma was created by immunizing Balb/c mice with HIV-1 gp120 (aa 308-322) fused to HBcAG particles. The resulting splenocytes were fused to Ag8653 myeloma cells.</p> <p>5F7 recognizes HIV-1 LAI gp160 and the V3 peptide RIQRGPGRAFVTIGK (aa 308-322) in ELISA. The antibody inhibits syncytium formation, RT activity, and p24 production <i>in vitro</i> (partial inhibition and retardation over 20 days).</p> <p>Please see the LANL HIV Immunology Database for more information.</p> <p>Applications: ELISA, Western Blot, IFA</p>
Recommended Storage:	Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. Albrecht von Brunn (Courtesy of CFAR, NIBSC)

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Isotype: IgG₁

References: von Brunn, A., Brand, M., Reichhuber, C., Morys-Wortmann, C., Deinhardt, F., & Schödel, F. (1993). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. *Vaccine*, 11(8), 817-824.
[PUBMED](#)

von Brunn A., Reichhuber C., Brand M., Bechowsky B., Gürtler L., Eberle J., Kleinschmidt A., Erfle V., Schödel F. (1993). The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. *Vaccines 93*, Cold Spring Harbor Press; Cold Spring Harbor, New York, 159-165.
[ARTICLE](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (5F7) from Dr. Albrecht von Brunn." Also include the references cited above in any publications.

Last Updated June 25, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.